14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SKIN vs VTAK: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, The Beauty Health Company (SKIN) is the stronger overall head-to-head candidate over Catheter Precision, Inc. (VTAK) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SKIN carries a Unified Composite Score of 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin), whereas VTAK carries 58.1/100 (HOLD) at $0.15 (N/M Forward P/E, -388.1% operating margin).
Composite vs. Pillar Nuance: While VTAK currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. SKIN 34.1/100 SELL), SKIN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (2.4% vs. -388.1% operating margin) and revenue trajectory (-2.1% vs. +380.7% YoY).
Technical & Structure Timing Caution: SKIN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 69.8); meanwhile VTAK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Medical Devices value chain with $548,639 market capitalization and -388.1% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ SKIN vs VTAK Key Questions & Quantitative Answers
As of Nov 16, 2026, The Beauty Health Company (SKIN) is the stronger overall head-to-head candidate over Catheter Precision, Inc. (VTAK) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SKIN carries a Unified Composite Score of 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin), whereas VTAK carries 58.1/100 (HOLD) at $0.15 (N/M Forward P/E, -388.1% operating margin). Composite vs. Pillar Nuance: While VTAK currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. SKIN 34.1/100 SELL), SKIN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (2.4% vs. -388.1% operating margin) and revenue trajectory (-2.1% vs. +380.7% YoY). Technical & Structure Timing Caution: SKIN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 69.8); meanwhile VTAK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SKIN leads the Growth & Scale pillar: SKIN posts -2.1% YoY revenue growth and +0.0% YoY earnings growth on $289M TTM revenue (67.2% gross margin, 2.4% operating margin), compared with VTAK at +380.7% YoY revenue growth and +0.0% YoY earnings growth on $1.9M TTM revenue (47.7% gross margin, -388.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SKIN cumulative revenue shifted +76.5% while VTAK shifted +0.0%. In operating R&D and SG&A reinvestment, SKIN deploys 64.8% of Rev ($187M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VTAK.
SKIN screens cheaper on headline valuation multiples. SKIN trades at 106.4x Forward P/E, 106.4x Trailing P/E, 0.93x PEG, and 0.9x EV/Revenue (5.8% FCF margin), whereas VTAK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SKIN (-30.1% ROE) versus VTAK (-111.3% ROE) capital efficiency.
In options market volatility and institutional positioning, SKIN carries 517.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-14.22β · 192% Vol realized risk). By comparison, VTAK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.19β · 76% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.